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ABSTRACT 
Introduction 
Neck of femur fractures are common in the comorbid, often anticoagulated, elderly. 
Non-vitamin K antagonist oral anticoagulants (NOACs) may affect patient outcomes. 
We aimed to evaluate whether hip fracture patients admitted on warfarin or NOAC 
therapy were at risk of operative delay, prolonged length of stay, or increased 
mortality. 
Methods 
We collected data for 845 patients admitted to our centre between October 2014 and 
December 2016. Multivariable linear regression analysis was performed to test the 
association between warfarin and NOAC therapy on time to surgery and length of 
stay. Variables in the regression model were age, sex, admission AMTS, pre-fracture 
mobility, ASA score, fracture type, and operation type. Fisher’s Exact Test was used 
to evaluate whether warfarin or NOAC therapy delayed surgery beyond 36 or 48 
hours, or decreased 30-day, 6-month, or 12-month survival. 
Results 
Time to surgery was delayed in anticoagulated patients (p=0.028). NOAC therapy 
was independently associated with increased time to surgery beyond 36 hours 
(p=0.001), although not beyond 48 hours (p=0.355), whereas warfarin therapy was 
not associated with either. Anticoagulation did not increase length of stay (p=0.331). 
Warfarin therapy significantly reduced 30-day survival (p=0.007), but NOAC therapy 
did not (p=0.244). Neither warfarin nor NOAC therapy affected further survival. 
Conclusions 
NOAC therapy delays time to surgery beyond the NHS England ‘Best Practice Tariff’ 
in hip fracture patients. We aim to prospectively investigate long-term outcomes. 
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Without a NOAC antidote, policy must change to ensure time-appropriate surgery for 
patients on NOACs. Preoperative involvement of the haematology team is essential. 
 
Key words 
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INTRODUCTION 
Hip fractures are common in the elderly and, in the UK alone, 65,000 patients aged 
60 and over sustained a hip fracture during 2015 (1). The incidence of hip fractures 
has increased over the last half-century, and projections indicate that this will 
continue and become a major demand on healthcare resources (2). Total UK annual 
hospital costs associated with hip fractures were recently estimated at more than £1 
billion (3). Length of stay is a major factor in the economic burden of this public 
health problem (1,3). 
 
In 2016, the National Institute for Health and Care Excellence (NICE) recommended 
that ‘Adults with hip fracture have surgery on a planned trauma list on the day of, or 
the day after, admission’ (4). Operative delay beyond 48 hours has been shown to 
increase 30-day all-cause mortality of hip fracture patients by 41% (5).There is also a 
financial incentive for National Health Service (NHS) Trusts to operate on hip 
fractures within 36 hours by way of the NHS England ‘Best Practice Tariff’ (BPT) 
introduced in 2010. In 2016, 18.7% of patients did not achieve best practice care 
based on a delayed time to theatre of more than 36 hours alone (1).  
 
Hip fractures are more common in multimorbid elderly patients, and they often have 
poor clinical outcomes with 1-year mortality rates approaching 36% (6). A recent 
study found that mortality is almost doubled for 8 years or more following the injury 
(7). A major cause of operative delay is anticoagulation, which many elderly patients 
require for cardiovascular comorbidities.  
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Anticoagulation with warfarin, a vitamin K antagonist (VKA), for atrial fibrillation (AF) 
or thromboembolic disease commonly causes this coagulopathy (8). This produces a 
raised international normalized ratio (INR) (9,10). Non-vitamin K antagonist oral 
anticoagulants (NOACs) have been recommended as alternatives to warfarin for 
stroke prevention in patients with non-valvular AF in several guidelines (11). NOACs 
act either as direct thrombin inhibitors (e.g. dabigatran) or direct factor Xa inhibitors 
(e.g. rivaroxaban or apixaban) thus prolonging the prothrombin time (PT). PT values 
(in seconds) cannot be converted to INR for NOACs because this has only been 
validated for VKAs (12). 
 
It was the suspicion of the clinicians in our trust that NOACs caused more operative 
delay since these drugs are irreversible (12,13). This has been reported rarely in the 
literature, with only a case report (14) and a small case-control study (10). We 
therefore decided to evaluate whether patients admitted with hip fractures on NOAC 
therapy were at risk of operative delay, prolonged length of hospital stay, or 
increased mortality. 
 
METHODS 
This retrospective cohort study is reported in accordance with the STROBE 
statement. Data for 845 consecutive patients admitted to a level 1 trauma centre with 
fracture of the femoral neck between October 2014 and December 2016 were 
extracted from the National Hip Fracture Database and collected from electronic 
patient records. One patient received no surgical treatment and was excluded from 
analysis (Figure 1). 83 of 844 surgically treated patients (9.8%) were receiving 
warfarin therapy on admission, and 32 of 844 surgically treated patients (3.8%) were 
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receiving NOAC therapy on admission (rivaroxaban (n = 19), apixaban (n = 8), and 
dabigatran (n = 5)) (Table 1). Warfarin and NOAC treatment status were collected 
from digital patient records manually. Internally verified data were collected on the 
age, sex, admission Abbreviated Mental Test Score (AMTS), pre-fracture mobility as 
assessed for the National Hip Fracture Audit, American Society of Anesthesiologists 
(ASA) score, fracture type (intracapsular – undisplaced, intracapsular – displaced, 
intertrochanteric, subtrochanteric), operation type (internal fixation, hemiarthroplasty, 
total hip arthroplasty, or other), time to surgery, length of stay, and 30-day, 6-month, 
and 12-month survival (Table 1). 
 
Statistical Analysis 
Descriptive and demographic analysis was first performed using Microsoft® Excel 
(15). Variables including age, sex, admission AMTS, pre-fracture mobility, ASA 
score, fracture type, and operation type were analysed in a multivariable linear 
regression analysis to test the association between warfarin and NOAC therapy on 
time to surgery and length of stay. A Fisher’s Exact Test was used to evaluate 
whether warfarin or NOAC therapy independently delayed surgery beyond 36 or 48 
hours, and whether either therapy decreased 30-day, 6-month, or 12-month survival. 
Another Fisher’s Exact Test was used in a subgroup analysis to determine if any 
NOAC (rivaroxaban, apixaban, or dabigatran) was associated with delayed surgery 
beyond 36 or 48 hours. All statistical analyses were performed using IBM® SPSS® 
Statistics (16). 
 
This project was approved by and registered with the clinical audit team in our 
centre. The National Hip Fracture Database is a national audit in the UK approved by 
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the National Health Service (NHS) England Health Research Authority (HRA) 
Confidentiality Advisory Group. 
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RESULTS 
 
Time to Surgery 
After controlling for age, sex, admission AMTS, pre-fracture mobility, ASA score, 
fracture type, and operation type, patients on anticoagulation therapy were found to 
go to theatre significantly later than those not anticoagulated (p=0.028) (Table 2a). 
As shown in Table 1, median time to surgery for patients on warfarin therapy was 27 
hours (IQR 13 hours), for patients on NOAC therapy was 29 hours (IQR 20 hours), 
and for patients on no anticoagulation therapy was 22 hours (IQR 10 hours). Fisher’s 
Exact Test then showed that NOAC therapy was independently associated with 
increased time to surgery beyond 36 hours (p=0.001), but not beyond 48 hours 
(p=0.355), whereas warfarin therapy was not associated with a delay beyond 36 
hours (p=0.089) or 48 hours (p=0.370) (Table 3). 
The subgroup analysis is also summarised in Table 3. Rivaroxaban therapy was not 
associated with a delay beyond 36 hours (p=0.207), however apixaban (p=0.050) 
and dabigatran (p=0.003) were. None were associated with a delay beyond 48 hours 
(Table 3). 
 
Length of stay 
The results of the multivariable linear regression analysis model when applied to 
length of stay are displayed in Table 2b. This shows no association between 
anticoagulation therapy and length of stay (p=0.331). The variables that significantly 
correlated with increased length of stay were admission AMTS, pre-fracture mobility, 
and ASA score (Table 2b). 
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Survival 
In view of the recent study extending to December 2016, 6-month survival data was 
unavailable for 170 patients (20%), and 12-month survival data was unavailable for 
391 patients (46%). Warfarin or NOAC therapy were tested independently against 
patient survival to 30 days, 6 months, and 12 months. Warfarin therapy was 
associated with a significant reduction in 30-day survival (p=0.007), but there was no 
association with warfarin therapy and longer-term survival, or with NOAC therapy 
and survival. 
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DISCUSSION 
Fractures of the neck of the femur are an ever-growing public health problem. Most 
often, these injuries befall the elderly, and so patients often present with multiple co-
morbidities that may require anticoagulation therapy. This anticoagulation may take 
the form of warfarin, or one of the newer non-vitamin K antagonist oral 
anticoagulants (NOACs). These all reduce the physiological capacity to stop 
bleeding and increase surgical risks; surgical interventions should not be performed 
unless they have been demonstrably counteracted, or sufficient time has passed for 
them to be cleared from the body. The effects of warfarin can be easily offset by 
giving the patient vitamin K, however the NOACs do not have antidotes that are 
readily available within the NHS and so they must be given enough time to clear. 
Dabigatran has a half-life of 14-18 hours depending on the degree of renal 
impairment, and so 2-4 days off this drug is thought necessary before high-bleeding 
risk procedures, whereas rivaroxaban and apixaban have much shorter half-lives of 
7-9 hours, and so need only be discontinued 24 hours before surgery (17). Local 
guidelines help the medical team balance the renal function of the patient with the 
estimated clearance of the drug, and therefore determine how long before surgery 
anticoagulant therapy should be interrupted. These drugs all have the potential to 
delay time to theatre and therefore delay the treatment that these surgical patients 
require, subsequently affecting outcomes. We found that patients in our cohort taking 
NOACs on admission were more likely to have delayed surgery. 
 
NOACs have been shown to have better bleeding profiles than warfarin for patients 
with atrial fibrillation and they obviate the need for routine blood monitoring (18). 
According to in vitro and animal studies, NOACs may also reduce the risk of 
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osteoporosis posed by vitamin K antagonist anticoagulants (19). These drugs, 
including warfarin, interfere with γ-carboxyglutamate formation by inhibiting the 
carboxylation of glutamate residues of proteins that are synthesized in bone, 
purportedly increasing the risk of osteoporosis, and by extension a fragility fracture 
(19,20). NOACs do not act on this pathway and so cannot pose such risks. These 
novel NOACs are therefore good medical drugs in an elderly population at risk from 
fragility fractures, but poor surgical drugs. 
 
We found that, when controlling for age, sex, admission AMTS, pre-fracture mobility, 
ASA score, fracture type, and operation type, patients on anticoagulation therapy 
went to theatre significantly later than those not. This delay has been reported 
several times before in the literature (9,10,21–23). However, to our knowledge, this 
study is the first to investigate the effect of three different NOACs on delayed time to 
surgery, and therefore should highlight which of these drugs are causing difficulty in 
the perioperative context. In this study, dabigatran and apixaban were particularly 
culpable and this could be explained by the longer half-life of dabigatran, or by the 
unfamiliarity of these drugs among surgeons managing hip fracture patients. 
 
We found no association between anticoagulation therapy and length of stay. 
Studies reported in the literature have yielded mixed results on this issue. While 
Ranhoff et al. (22) and more recently Lawrence et al. (23) found that patients 
receiving warfarin on admission to hospital had longer lengths of stay, Eardley et al. 
(9) found similar results to us in a study of 1024 patients. 
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We found a reduced 30-day survival among patients taking warfarin, but not those 
taking NOACs. Reduced survival of hip fracture patients admitted on warfarin 
therapy has recently been reported (23). The lack of association with NOAC therapy 
may in part be due to the low patient numbers in our study. Regardless, clinicians 
involved in the operative work-up and post-operative care should be aware of a 
possible association between anticoagulation therapy and increased mortality in 
patients admitted with a hip fracture, and work together to manage such patients with 
care. 
 
The ability to reverse NOACs in patients presenting with a fracture requiring surgical 
intervention is a pressing need. Infusion with prothrombin complex concentrate 
(PCC) and fresh frozen plasma (FFP) have been used in mouse models to reverse 
the effects of dabigatran, but despite some success, have not shown ultimately 
convincing results (24). PCC has also been trialled in humans with some success 
although this does not represent an ideal solution in the clinical situation (25). 
Dialysis is possible in dabigatran, but not factor Xa inhibitors since their plasma 
protein binding is too high (26). Again, this does not represent a viable clinical option 
for a multimorbid and ageing surgical population. Specific antidotes including 
monoclonal antibodies are being produced and trialled but nothing is currently 
available within the NHS as yet (26). 
 
There were several limitations to our study. Although our centre is unique in the UK 
with a fully computerised patient records (Epic Systems Corporation, Verona, WI) 
allowing retrospective chart reviews (27,28), the retrospective data collection could 
not account for some variables in our analysis such as other comorbidities, and 
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precise details of when anticoagulation therapy was halted over the perioperative 
period. This slightly pragmatic snapshot, however, reflects the reality of surgical 
practice. Further, we could not clearly delineate why surgery was delayed in each 
case. According to the 2016 National Hip Fracture Database (NHFD) report, 18.7% 
of patients failed to achieve best practice care because of delays to theatre, and half 
of these (nearly 6,000 patients) were delayed for administrative reasons (1). Another 
reason pertinent to our trauma centre could be the competition for theatre time which 
has significantly increased, delaying surgical management of hip fracture patients, 
since becoming a major trauma centre, with associated increases in morbidity and 
mortality (29). 
 
This study reports the most patients on NOACs hospitalized with hip fractures in the 
literature to date, with only a case report (14); and a case-control study by Tran et al. 
noting similar findings (10).The number of patients evaluated in our study however 
was not sufficient for a thorough subgroup analysis. Despite the relatively large 
overall cohort, only 83 patients were on warfarin, and 32 were on NOACs. This could 
explain why we did not find significance in the delay to surgery among the patient 
group on warfarin which has been reported by many others (9,21–23,30). However, 
this could also stem from a change in the process of warfarin reversal at our centre. 
If at first vitamin K administration does not sufficiently reduce the INR, then patients 
are given prothrombin complex concentrate in the form of Beriplex or Octaplex to 
instantly reverse the effect of warfarin.  
 
The UK Best Practice Tariff (BPT) may put pressure on surgical teams to get 
patients to theatre quickly in order to avoid any financial penalty. Many 
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anticoagulated patients cannot meet ‘best practice’ without incurring the risks of 
surgery with a high likelihood of bleeding because this does not allow sufficient time 
for these novel anticoagulant drugs to be cleared from the body. Such was the case 
in our cohort. It is therefore important to note that there is a potential financial 
implication in the safe and timely management of these patients. Until an antidote 
becomes widely available within the NHS, the National Institute for Health and Care 
Excellence (NICE) must update its guidance to appreciate the increasing number of 
patients on NOACs presenting with neck of femur fractures who require delayed 
surgery that is safe and does not promote excessive haemodynamic risk. 
 
There are clearly an increasing number of frail and elderly hip fracture patients who 
are presenting to our trauma centres on anticoagulant therapy. To prepare for the 
medical complexity of this growing public health burden, it is crucial that orthopaedic 
surgeons and orthogeriatricians in the multi-disciplinary team familiarise themselves 
with these NOACs. These drugs show differing pharmacological characteristics, 
crucially different half-lives, and it is important that the team is aware of these 
differences in order to provide surgery that is timely but patient-centred and crucially, 
safe. 
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TABLES 
Table I 
 
Abbreviations: 
Table 1. Sample description for patients not taking anticoagulation therapy, and those on warfarin 
or NOAC therapy 
Measure No 
anticoagulation 
On 
warfarin 
On 
NOAC 
Total 
Number of patients (%) 729 (86) 83 (10) 32 (4) 844 (100) 
Age, years (median, IQR) 85 (12) 84 (10) 87 (11) 85 (12) 
Female, number (%) 535 (73) 57 (69) 26 (81) 618 (73) 
AMTS, median (IQR) 9 (6) 10 (3) 8 (5) 7 (4-10) 
Fracture type, number (%) 
    
      Intracapsular - undisplaced 11 (2) 0 (0) 1 (3)  12 (1) 
      Intracapsular - displaced 386 (53) 54 (65) 19 (59) 459 (54) 
      Intertrochanteric 275 (38) 23 (28) 9 (28) 307 (36) 
      Subtrochanteric 57 (8) 6 (7) 3 (9) 66 (8) 
ASA score, number (%)a 
    
      5 2 (0) 0 (0) 0 (0) 2 (0) 
      4 78 (12) 9 (14) 7 (23) 94 (13) 
      3 299 (48) 44 (67) 20 (65) 363 (50) 
      2 175 (28) 8 (12) 2 (6) 185 (26) 
      1 71 (11) 5 (8) 2 (6) 78 (11) 
Operation type, number (%) 
    
      Internal fixation 374 (51) 31 (37) 12 (38) 417 (49) 
      Hemiarthroplasty 313 (43) 50 (60) 19 (59) 382 (45) 
      THA 39 (5) 2 (2) 0 (0) 41 (5) 
      Other 3 (0) 0 (0) 1 (3)  4 (0) 
Time to surgery 
    
      Median hours (IQR) 22 (10) 27 (13) 29 (20) 22 (11) 
      <36 hours, number (%) 618 (85) 64 (77) 19 (59) 701 (83) 
      <48 hours, number (%)b 682 (94) 79 (95) 29 (91) 790 (94) 
Length of stay, median days 
(IQR)c 
12 (11) 12 (7) 14 (9) 12 (10) 
Survival, number (%) 
    
      30-day 697 (96) 73 (88) 30 (94)  800 (95) 
      6-monthd 478 (82) 55 (81) 20 (83) 553 (82) 
      12-monthe 301 (76) 33 (80) 12 (71) 346 (76) 
aASA score missing for 122 patients; bincludes patients operated on in <36 hours; cLength of stay 
missing for 25 patients; d 6-month survival missing for 170; e 12-month survival missing for 391 
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NOAC – non-vitamin K antagonist oral anticoagulants 
IQR – interquartile range 
AMTS – abbreviated mental test score 
ASA – American Society of Anesthesiologists  
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Table II 
 
Abbreviations: 
AMTS – abbreviated mental test score 
ASA – American Society of Anesthesiologists 
 
 
 
  
Table 2. Multivariable regression results showing factors related to (a) time to surgery 
(hours) (b) length of stay (days) 
(a) Time to surgery (hours) (b) Length of stay (days) 
Factor Standardized 
Beta 
Coefficient 
p value Factor Standardized 
Beta 
Coefficient 
p value 
Age -0.031 0.443 Age 0.047 0.241 
Sex 0.078 0.036* Sex 0.050 0.168 
AMTS 0.003 0.950 AMTS -0.170 0.000* 
Pre-fracture 
mobility 
0.049 0.262 Pre-fracture 
mobility 
-0.109 0.011* 
ASA score 0.060 0.127 ASA score 0.127 0.001* 
Fracture type 0.063 0.199 Fracture type 0.017 0.724 
Operation type 0.128 0.010* Operation type -0.037 0.434 
Anticoagulation 0.083 0.028* Anticoagulation 0.230 0.331 
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Table III 
 
 
Abbreviations: 
NOAC – non-vitamin K antagonist oral anticoagulants  
Table 3. Fisher’s Exact Test results to show if warfarin or NOAC therapy was 
associated with delayed surgery beyond 36 or 48 hours 
Survival Anticoagulation therapy p value (1-sided test) 
Delayed >36 hours Warfarin 0.089 
 NOAC 0.001* 
 - Rivaroxaban 0.207 
 - Apixaban 0.050* 
 - Dabigatran 0.003* 
Delayed >48 hours Warfarin 0.370 
 NOAC 0.355 
  - Rivaroxaban 0.281 
  - Apixaban 0.108 
  - Dabigatran 0.282 
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FIGURE LEGENDS 
 
Figure 1. Flow diagram showing selection of patient data 
